Regent Pacific Group Ltd
Company Profile
Business description
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
Contact
5 Queen's Road Central
8th Floor, Henley Building
Hong Kong
HKGT: +852 25146111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
World’s largest miner benefits from copper boom
stocks
ASX retailer sees weaker sales growth as conditions soften
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.80 | 9.10 | 0.10% |
| CAC 40 | 8,509.36 | 70.24 | -0.82% |
| DAX 40 | 26,128.36 | 210.25 | -0.80% |
| Dow JONES (US) | 53,343.40 | 116.38 | -0.22% |
| FTSE 100 | 10,728.04 | 7.74 | 0.07% |
| HKSE | 25,513.36 | 42.21 | 0.17% |
| NASDAQ | 26,289.71 | 355.20 | -1.33% |
| Nikkei 225 | 65,724.25 | 1,736.48 | -2.57% |
| NZX 50 Index | 13,913.20 | 47.02 | 0.34% |
| S&P 500 | 7,691.76 | 53.30 | -0.69% |
| S&P/ASX 200 | 9,040.00 | 11.40 | 0.13% |
| SSE Composite Index | 3,924.14 | 66.17 | -1.66% |